XPAR
SAN
Market cap101bUSD
Jun 18, Last price
73.34EUR
1D
-2.06%
1Q
-5.72%
Jan 2017
-4.63%
IPO
25.26%
Name
Sanofi SA
Chart & Performance
P/E
15.86
P/S
1.99
EPS
4.63
Div Yield, %
5.13%
Shrs. gr., 5y
-13.02%
Rev. gr., 5y
3.31%
Revenues
44.29b
-3.80%
Net income
5.56b
+2.96%
CFO
9.08b
-11.47%
Dividend
May 05, 20264.12 EUR/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of innovative therapeutic solutions across North America, Europe, and other international markets. Its operations are organized into three principal segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical division, Sanofi offers a diverse portfolio of specialty care products, including advanced human monoclonal antibodies. These target a range of serious conditions such as multiple sclerosis, neurological disorders, various inflammatory and immunological diseases, rare genetic disorders, oncology, and rare blood conditions. The company also provides essential medicines for diabetes, cardiovascular health, and a selection of established prescription drugs. The Vaccines segment delivers crucial immunizations, encompassing pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside a variety of vaccines for adults, including those for influenza, boosters, meningitis, and specific travel or endemic diseases. Sanofi's Consumer Healthcare arm supplies a broad spectrum of over-the-counter products, addressing needs like allergy relief, cough and cold symptoms, pain management, liver support, physical and mental wellness (including probiotics and digestive aids), and nutritional supplements. This segment also includes various topical and skincare solutions, such as daily body lotions, anti-itch treatments, moisturizing creams, and powders for skin conditions like eczema. Beyond its current offerings, Sanofi maintains a robust pipeline of pharmaceutical products and vaccines in various stages of development. The company actively engages in strategic collaborations, including a partnership with GlaxoSmithKline for the development of a recombinant Covid-19 vaccine, a research alliance with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and licensing option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company officially rebranded as Sanofi in May 2011, having previously operated under the name Sanofi-Aventis.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||